U.S., Aug. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07118462) titled 'HighCycle Study: Acetazolamide, High Altitude and Plasma Volume' on Aug. 05.
Brief Summary: Each year, millions of people living at low altitude (= 2,500 m) for work, tourism, or sports activities. These individuals are exposed to hypobaric hypoxia, which can trigger acute mountain sickness (AMS)-the most common form of altitude-related illness. Therefore, understanding the physiological responses to hypoxia that allow acclimatization, as well as the pathophysiology of acute mountain sickness, is of primary importance.
The hematological response to high-altitude exposure initially includes a reduction in plasma volume (PV), leading...